In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer |
| |
| Authors: | Anne E Lykkesfeldt Katrine L Henriksen Birgitte B Rasmussen Hironobu Sasano Dean B Evans Susanne M?ller Bent Ejlertsen Henning T Mouridsen |
| |
| Affiliation: | (1) Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, DK- 2100 Copenhagen ?, Denmark;(2) Department of Pathology, Herlev Hospital, DK-2730, Denmark;(3) Department of Pathology, Tohoku University School of Medicine, 980-8575 Sendai, Japan;(4) Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland;(5) Danish Breast Cancer Cooperative Group, Rigshospitalet, DK- 2100 Copenhagen ?, Denmark;(6) Department of Oncology, Rigshospitalet, DK- 2100 Copenhagen ?, Denmark;(7) Danish Breast Cancer Cooperative Group, Rigshospitalet, DK- 2100 Copenhagen ?, Denmark |
| |
| Abstract: | Background New, third-generation aromatase inhibitors (AIs) have proven comparable or superior to the anti-estrogen tamoxifen for treatment of estrogen receptor (ER) and/or progesterone receptor (PR) positive breast cancer. AIs suppress total body and intratumoral estrogen levels. It is unclear whether in situ carcinoma cell aromatization is the primary source of estrogen production for tumor growth and whether the aromatase expression is predictive of response to endocrine therapy. Due to methodological difficulties in the determination of the aromatase protein, COX-2, an enzyme involved in the synthesis of aromatase, has been suggested as a surrogate marker for aromatase expression. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
